Hong Kong, Aug. 13, 2025 (GLOBE NEWSWIRE) -- BUUU Group Limited (Nasdaq: BUUU) (the “Company”), an established meetings, incentives, conferences and exhibitions (“MICE”) solutions provider based in Hong Kong , today announced the pricing of its initial public offering (the “Offering”) of 1,500,000 Class A ordinary shares (the “Class A Ordinary Shares”), at a price of $4.00 per Class A Ordinary Share (the “Offering Price”). The Class A Ordinary Shares are expected to begin trading on the Nasdaq Capital Marke ...

Not for distribution to U.S. News wire services or dissemination in the U.S. VANCOUVER, British Columbia, Aug. 13, 2025 (GLOBE NEWSWIRE) -- The Keg Royalties Income Fund (the “Fund”) (TSX: KEG.UN) is pleased to announce its financial results for the three months ended June 30, 2025 (the “quarter”) and the six months ended June 30, 2025 (“YTD”). On May 5, 2025, the Fund entered into a non-binding letter of intent to which one or more affiliates of Fairfax Financial Holdings Limited (“Fairfax”) will acquire a ...

Core Viewpoint - BioSig Technologies, Inc. has announced its intention to offer shares of common stock through an underwritten public offering, following its recent merger with Streamex Exchange Corporation [1] Group 1: Offering Details - The offering will include shares of common stock or pre-funded warrants, with the completion subject to market conditions [1] - The net proceeds from the offering are intended for purchasing gold bullion, working capital, and general corporate purposes [1] - Clear Street and Needham & Company are acting as joint book-running managers for the offering [2] Group 2: Regulatory Information - The offering is made pursuant to a shelf registration statement on Form S-3, declared effective by the SEC on December 17, 2024 [3] - A preliminary prospectus supplement will be filed with the SEC, and interested parties are encouraged to read the documents for more information [3] Group 3: Company Background - BioSig Technologies is a medical device technology company specializing in advanced digital signal processing technology for electrophysiology [6] - The PURE EP™ Platform developed by the company allows for real-time acquisition of raw signal data, enhancing procedural success in ablation treatments [7] - Streamex, a wholly owned subsidiary of BioSig, focuses on gold tokenization and building infrastructure for the gold market [5]

Core Insights - The company is making significant progress in its clinical operations and pipeline, particularly with govorestat for the treatment of CMT-SORD, and is preparing for a meeting with the FDA in Q3 2025 regarding a potential NDA submission [2][3] - A new sponsored Urine Sorbitol Assay has been launched to aid in the identification of patients with CMT-SORD, which is available at no cost to healthcare providers [3] - The company presented full 12-month clinical results from the INSPIRE Phase 2/3 trial of govorestat, showing slowed disease progression and statistically significant improvements in key secondary endpoints [3] CMT-SORD - A meeting with the FDA is scheduled to discuss the NDA submission strategy for govorestat, focusing on its treatment for CMT-SORD [3] - The company launched a Urine Sorbitol Assay to help healthcare providers identify suspected cases of CMT-SORD, removing barriers to diagnosis and treatment [3] - Full clinical results from the INSPIRE trial indicated that govorestat is generally safe and well-tolerated, with significant improvements in various health metrics [3] Classic Galactosemia - The company is reviewing its development program for govorestat in Classic Galactosemia, including responses to the Complete Response Letter from the FDA [4] PMM2-CDG - Results from an ongoing trial of govorestat for PMM2-CDG will be presented at the 2025 ASHG Annual Meeting, highlighting the drug's potential in treating this ultra-rare disease [5] Corporate Developments - The company entered into an out-licensing agreement with Biossil, Inc. for AT-001, gaining upfront payment and potential future royalties [9] - Key leadership changes were made, promoting Evan Bailey, M.D., to Chief Medical Officer and Dottie Caplan to Executive Vice President [9] Financial Results - As of June 30, 2025, cash and cash equivalents totaled $30.4 million, down from $79.4 million at the end of 2024 [7] - Research and development expenses for Q2 2025 were $9.9 million, slightly down from $10.0 million in Q2 2024 [7] - General and administrative expenses increased to $13.2 million in Q2 2025 from $10.6 million in Q2 2024, contributing to a net loss of $21.3 million for the quarter [7]

Core Insights - Mobix Labs achieved record adjusted gross margins of 60.6%, significantly up from 42.7% in the previous quarter and 40.3% year-over-year, indicating a strong shift towards higher-margin products and improved operational efficiency [5][11] - The company reported adjusted gross profit of $1.42 million for Q3 2025, reflecting a 32.7% increase from $1.07 million in the prior quarter and a 71.1% increase from $0.83 million year-over-year [5][11] - Year-over-year revenue growth reached $2.35 million, a 14.2% increase compared to $2.06 million in Q3 2024, demonstrating strong demand despite shipment timing variances [5][11] - The adjusted loss from operations improved to $1.17 million, a 64.2% reduction from the $3.27 million loss in the prior quarter [5][11] - For the first nine months of fiscal 2025, adjusted gross profit surged to $4.21 million, up 239.5% from $1.24 million in the same period last year, with adjusted gross margin expanding to 52.4% from 35.6% [5][11] Recent Business Highlights - The integration of RaGE Systems is enabling Mobix Labs to deliver faster, turnkey solutions, enhancing its position in aerospace and defense markets [5] - The company has expanded its relationships with top-tier defense contractors, positioning itself for multi-year program opportunities [5] - Mobix Labs announced an unsolicited proposal to acquire Peraso, Inc. at a 20% premium to its 30-day average share price, indicating a strategic commitment to market expansion and revenue growth [5] - The ongoing focus on expanding product offerings in RF/mmWave, EMI filtering, and next-generation connectivity is creating a robust pipeline for high-margin solutions in emerging 5G, aerospace, and defense applications [5]

Core Insights - Bird Construction is executing its 2025-2027 Strategic Plan, focusing on sectors with long-term demand drivers and maintaining a risk-balanced work program to drive growth and margin accretion [1] - The company has a record backlog of $4.6 billion, which positions it well to capitalize on future opportunities once market uncertainties resolve [1][2] Financial Performance - In Q2 2025, Bird's construction revenue was $850.8 million, a decrease of 2.6% from $873.5 million in Q2 2024 [5][7] - Net income for Q2 2025 was $20.3 million, down from $21.4 million in Q2 2024, while adjusted earnings increased by 18% to $27.6 million [5][6] - Adjusted EBITDA for Q2 2025 was $54.9 million, representing a margin of 6.5%, up from 5.3% in the prior year [5][8] Backlog and Securements - Bird secured almost $1.2 billion in additional work in Q2 2025, increasing its backlog to a record $4.6 billion [2][8] - Year-to-date securements totaled $2.5 billion, nearly $1.0 billion higher than the previous year [8] Operational Highlights - The company generated strong operational cash flow of $54.5 million in Q2 2025, a 14.8% increase from the same quarter in 2024 [8] - Bird's liquidity position remains robust, with $142.6 million in cash and an additional $231.7 million available under its credit facility [8] Project Awards - In Q2 2025, Bird was awarded five projects valued at over $650 million, including significant contracts in infrastructure and industrial sectors [8][14]

Core Insights - Wesdome Gold Mines Ltd. reported strong financial results for Q2 2025, with significant increases in revenue, net income, and cash flow, despite challenges in production at Kiena due to equipment constraints [1][6][50]. Financial Performance - Consolidated revenue for Q2 2025 was CAD 208.5 million, a 63% increase from CAD 127.8 million in Q2 2024 [8]. - Gross profit rose by 146% year-over-year to CAD 132.2 million, with a cash margin growing by 96% to CAD 149.4 million [6][8]. - Net income for Q2 2025 reached CAD 82.7 million, or CAD 0.55 per share, nearly tripling from CAD 29.1 million in Q2 2024 [6][8]. - EBITDA increased by 104% to CAD 138.4 million compared to Q2 2024 [6][8]. - As of June 30, 2025, liquidity stood at CAD 530 million, including CAD 187.6 million in cash [6][8]. Production Highlights - Consolidated gold production was 42,781 ounces, a 3% decrease compared to Q2 2024 [6][8]. - At Eagle River, gold production increased to 25,612 ounces, up from 19,272 ounces in Q2 2024, driven by a 44% increase in average grade [12][16]. - Kiena's production decreased by 31% to 17,169 ounces due to equipment constraints and lower average grades [33][38]. Cost Metrics - Cost of sales per ounce sold decreased by 1% to USD 932, while all-in sustaining costs (AISC) per ounce sold increased by 6% to USD 1,528 [6][8]. - Cash costs per ounce sold declined to USD 872 in Q2 2025 from USD 1,239 in Q2 2024 [18][40]. - AISC per ounce sold decreased by 24% to USD 1,394 compared to Q2 2024 [20][41]. Operational Developments - Eagle River's mill throughput was impacted by an 18-day maintenance shutdown, but overall throughput for H1 2025 increased by 4% compared to the same period in 2024 [14][15]. - Kiena is focusing on developing additional mining horizons to improve production flexibility and reliability [4][54]. Strategic Initiatives - The acquisition of Angus Gold has expanded Eagle River's land package and is expected to increase exploration spending by approximately CAD 5 million in 2025 [6][7]. - The company is investing in infrastructure and technical studies to enhance operational efficiency and support future growth [5][56]. 2025 Guidance Update - Eagle River's production guidance has been raised to 105,000 to 115,000 ounces, while Kiena's guidance has been updated to 80,000 to 90,000 ounces due to production challenges [52][54]. - AISC expectations for Kiena have been revised to USD 1,400 to USD 1,575, reflecting increased costs associated with maintenance and operational optimization [55].

Core Insights - PharmaCorp RX Inc. has secured a credit agreement with Canadian Imperial Bank of Commerce (CIBC) for up to $20,500,000 in committed credit facilities, which includes a $10,000,000 accordion feature and a $1,000,000 Visa credit facility to support its acquisition strategy and operational expansion [1][4][8] Credit Facilities - The credit facilities consist of a $17,500,000 committed acquisition term facility with a $10,000,000 accordion feature, allowing for increased borrowing capacity as acquisition opportunities arise, and a $3,000,000 committed revolving operating line for working capital [8] - A separate $5,000,000 credit facility is established to support the Pharmacist Co-Ownership Program, aimed at addressing the capital access challenges faced by pharmacists [2][3] Pharmacist Co-Ownership Program - The Pharmacist Co-Ownership Program provides loans to pharmacists wishing to acquire ownership in the PharmaCorp pharmacy where they work, financing up to 100% of their equity investment with competitive rates and repayment terms of up to 15 years [3][4] - This program is designed to remove barriers to ownership and facilitate long-term wealth creation for pharmacists through co-ownership with PharmaCorp [4] Company Operations - PharmaCorp currently operates four PharmaChoice Canada bannered pharmacies and plans to continue acquiring additional PharmaChoice Canada branded pharmacies as they become available [5] - The company is also open to acquiring independently owned non-PharmaChoice Canada bannered pharmacies and will operate them under the PharmaChoice Canada banner post-acquisition [5][6]

Core Insights - Stantec reported strong financial results for Q2 2025, with net revenue reaching $1.6 billion, a 6.9% increase year-over-year, driven by 4.8% organic growth across all regions and business units [3][8][14] - The company has revised its 2025 guidance upward, expecting net revenue growth of 10% to 12%, adjusted EBITDA margin of 17% to 17.4%, and adjusted EPS growth of 18.5% to 21.5% [5][6][12] - Stantec's contract backlog increased to $7.9 billion, reflecting a 9.9% year-over-year growth, with notable organic growth contributions from all regional units [8][21] Financial Performance - Net revenue for Q2 2025 was $1.6 billion, up $103.4 million from Q2 2024, with organic growth of 4.8% [3][14] - Adjusted EBITDA rose 15.0% to $284.4 million, with an adjusted EBITDA margin of 17.8%, a 120 basis point increase from the previous year [3][14] - Diluted EPS increased by 63.0% to $1.19, while adjusted EPS grew 21.4% to $1.36 [3][14] Regional Performance - Canada achieved organic growth of 6.2%, the United States 4.4%, and Global operations 4.3% [3][20] - The Water segment saw significant organic growth of 12.4%, while Energy & Resources delivered 9.5% organic growth [3][14] Acquisitions and Strategic Moves - Stantec completed several acquisitions, including Ryan Hanley, Cosgroves, and Page, enhancing its capabilities in various sectors [4][8][14] - The acquisition of Page, a 1,400-person firm, is expected to strategically complement Stantec's Buildings business [8][14] Outlook and Guidance - The company has increased its guidance for 2025, reflecting strong year-to-date performance and the impact of recent acquisitions [5][6][12] - Adjusted net income is expected to exceed 8.8% of net revenue, with adjusted ROIC projected to be above 12.5% [12][14] Backlog and Cash Flow - Contract backlog reached $7.9 billion, indicating approximately 12 months of work, with 9% organic growth contributing to this increase [8][21] - Operating cash flows increased by 79.4% to $134.0 million, demonstrating solid operational performance and effective collection efforts [14][17]

Core Viewpoint - Stardust Power Inc. is making steady progress in its lithium product development, with a focus on engineering, permitting, and infrastructure, while also beginning third-party validation of its FEL-3 study, which is expected to reduce project risk [2][5] Business Updates - The company successfully closed a public offering on June 18, 2025, raising approximately $4.52 million, including proceeds from the underwriters' partial exercise of their overallotment option [5] - A strategic partnership was formed with Ohio University to advance lithium extraction and refining technologies, aimed at accelerating research on lithium production from brine sources [5] - The company is developing a lithium processing facility in Muskogee, Oklahoma, with an anticipated capacity of producing up to 50,000 metric tons per annum of battery-grade lithium [7] Financial Highlights - As of June 30, 2025, the company had cash and cash equivalents of approximately $2.6 million and no long-term debt [3] - The net loss for the second quarter of 2025 was $3.7 million, compared to a loss of $2.7 million for the same quarter in the previous year [6] - Loss per share improved to $(0.06) for the second quarter of 2025, compared to $(0.07) for the prior year quarter [6] - Net cash used in operating activities increased to $4.5 million for the six months ended June 30, 2025, compared to $2.1 million for the prior year period [6] - Net cash used in investing activities was $2.2 million for the six months ended June 30, 2025, compared to $0.5 million for the prior year period [6] - Net cash provided by financing activities was $8.4 million for the six months ended June 30, 2025, compared to $2.0 million for the prior year period [6]